"Here's food for thought - what if the sub-therapeutic doses the first couple of cohorts get actually knock down a significant percentage of the virus?"
Dr KSS, has canvassed this and suggests it might be possible however I think it was Hoyland who said it probably isnt going to happen. He gave an immune response as the reason.
A response by the virus, however small in log reduction would be enormous.
It looks like the second patient will be dosed while BLTO will be in suspension. They won't give it to them until they know all is OK with patient one. That could be more market moving than the first patient being dosed.
The market knows its only ten to fourteen days away and it's likely priced in.
"Here's food for thought - what if the sub-therapeutic doses the...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)